

Christopher C Rowe

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9053112/christopher-c-rowe-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

237
papers

27,316
citations

63
h-index

164
g-index

336
ext. papers

33,479
ext. citations

5.9
avg, IF

6.54
L-index

#	Paper	IF	Citations
237	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. <i>JAMA Neurology</i> , 2022 ,	17.2	9
236	APOE ϵ resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies.. <i>Alzheimer's and Dementia</i> , 2022 ,	1.2	2
235	Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum.. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022 , 14, e12307	5.2	2
234	Association between amyloid-beta deposition and cortical thickness in dementia with Lewy bodies.. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022 , 48674221081773	2.6	
233	The Association Between Alzheimer's Disease-Related Markers and Physical Activity in Cognitively Normal Older Adults.. <i>Frontiers in Aging Neuroscience</i> , 2022 , 14, 771214	5.3	1
232	Mesial temporal tau in amyloid- β -negative cognitively normal older persons.. <i>Alzheimer's Research and Therapy</i> , 2022 , 14, 51	9	1
231	Insulin resistance, cognition and Alzheimer's disease biomarkers: Evidence that CSF A β 2 moderates the association between insulin resistance and increased CSF tau levels.. <i>Neurobiology of Aging</i> , 2022 , 114, 38-48	5.6	0
230	Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study. <i>Biomedicine</i> , 2022 , 10, 1045	4.8	1
229	Brain age in chronic traumatic brain injury.. <i>NeuroImage: Clinical</i> , 2022 , 35, 103039	5.3	
228	Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid- β <i>Neurobiology of Disease</i> , 2022 , 105783	7.5	1
227	Head-to-head comparison of cerebral blood flow single-photon emission computed tomography and F-fluoro-2-deoxyglucose positron emission tomography in the diagnosis of Alzheimer disease. <i>Internal Medicine Journal</i> , 2021 , 51, 1243-1250	1.6	5
226	AI Imaging in Aging, Alzheimer's Disease, and Other Neurodegenerative Conditions 2021 , 283-343		
225	The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives.. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021 , 7, e12226	6	1
224	What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 614-619	8.9	5
223	Association of β Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals. <i>Neurology</i> , 2021 , 96, e662-e670	6.5	10
222	Early detection of amyloid load using F-florbetaben PET. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 67	9	4
221	Does cognitive decline occur decades after moderate to severe traumatic brain injury? A prospective controlled study. <i>Neuropsychological Rehabilitation</i> , 2021 , 1-20	3.1	0

220	A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [F]flutemetamol amyloid PET images. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2183-2199	8.8	3
219	Advances in Brain Amyloid Imaging. <i>Seminars in Nuclear Medicine</i> , 2021 , 51, 241-252	5.4	10
218	Androgen receptor CAG repeat length as a moderator of the relationship between free testosterone levels and cognition. <i>Hormones and Behavior</i> , 2021 , 131, 104966	3.7	1
217	Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease. <i>Journal of Alzheimer's Disease Reports</i> , 2021 , 5, 443-468	3.3	15
216	Longitudinal Trajectories in Cortical Thickness and Volume Atrophy: Superior Cognitive Performance Does Not Protect Against Brain Atrophy in Older Adults. <i>Journal of Alzheimer's Disease</i> , 2021 , 81, 1039-1052	4.3	
215	Aggregation of Abnormal Memory Scores and Risk of Incident Alzheimer's Disease Dementia: A Measure of Objective Memory Impairment in Amnesic Mild Cognitive Impairment. <i>Journal of the International Neuropsychological Society</i> , 2021 , 27, 146-157	3.1	3
214	Mesial temporal tau is related to worse cognitive performance and greater neocortical tau load in amyloid-negative cognitively normal individuals. <i>Neurobiology of Aging</i> , 2021 , 97, 41-48	5.6	12
213	Non-negative matrix factorisation improves Centiloid robustness in longitudinal studies. <i>NeuroImage</i> , 2021 , 226, 117593	7.9	3
212	Is Associated with Amyloid- β and τ -Related Cognitive Decline in Cognitively Normal Adults. <i>Journal of Alzheimer's Disease Reports</i> , 2021 , 5, 111-120	3.3	1
211	PET Imaging of brain muscarinic receptors with F-Fluorobenzyl-Dexetimide: A first in human study. <i>Psychiatry Research - Neuroimaging</i> , 2021 , 316, 111354	2.9	2
210	Relationship between amyloid and tau levels and its impact on tau spreading. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2225-2232	8.8	8
209	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. <i>Neurology</i> , 2021 , 96, e1632-e1645	6.5	4
208	Quantitative thresholds for 18F-florbetaben PET for the detection of low amyloid load. <i>Alzheimer's and Dementia</i> , 2020 , 16, e042933	1.2	
207	One year tau progression measured with F-18 MK6240 PET. <i>Alzheimer's and Dementia</i> , 2020 , 16, e044987	1.2	
206	Basal forebrain atrophy and tau pathology are correlated in prodromal AD. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046111	1.2	
205	Relationships Between Plasma Lipids Species, Gender, Risk Factors, and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020 , 76, 303-315	4.3	7
204	Plasma transferrin and hemopexin are associated with altered A β uptake and cognitive decline in Alzheimer's disease pathology. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 72	9	8
203	Impact of APOE- ϵ carriage on the onset and rates of neocortical A β amyloid deposition. <i>Neurobiology of Aging</i> , 2020 , 95, 46-55	5.6	15

202	Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020 , 12, e12005	5.2	17
201	Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 22	9	39
200	Human biodistribution and internal dosimetry of 4-[F]fluorobenzyl-dexetimide: a PET radiopharmaceutical for imaging muscarinic acetylcholine receptors in the brain and heart. <i>EJNMMI Research</i> , 2020 , 10, 61	3.6	2
199	Comorbidity of Cerebrovascular and Alzheimer's Disease in Aging. <i>Journal of Alzheimer's Disease</i> , 2020 , 78, 321-334	4.3	2
198	Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-A β load and cerebrospinal fluid A β in a pilot study of Alzheimer's disease. <i>Neuroscience Letters</i> , 2020 , 731, 135078	3.3	1
197	Amyloid- τ , and 18F-Fluorodeoxyglucose Positron Emission Tomography in Posttraumatic Stress Disorder. <i>Journal of Alzheimer's Disease</i> , 2020 , 73, 163-173	4.3	1
196	Influence of Comorbidity of Cerebrovascular Disease and Amyloid- τ in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020 , 73, 897-907	4.3	12
195	Longitudinal exploration of cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma: protocol for a feasibility study. <i>BMJ Open</i> , 2020 , 10, e038312	3	1
194	Severe Obstructive Sleep Apnea Is Associated with Higher Brain Amyloid Burden: A Preliminary PET Imaging Study. <i>Journal of Alzheimer's Disease</i> , 2020 , 78, 611-617	4.3	11
193	Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer's disease. <i>Nature Communications</i> , 2020 , 11, 5698	17.4	23
192	In vivo microstructural heterogeneity of white matter lesions in healthy elderly and Alzheimer's disease participants using tissue compositional analysis of diffusion MRI data. <i>NeuroImage: Clinical</i> , 2020 , 28, 102479	5.3	10
191	Longitudinal evaluation of the natural history of amyloid- τ in plasma and brain. <i>Brain Communications</i> , 2020 , 2, fcaa041	4.5	6
190	Plasma Amyloid- τ Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020 , 77, 1057-1065	4.3	14
189	Rates of age- and amyloid β -associated cortical atrophy in older adults with superior memory performance. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 566-575	5.2	12
188	Klotho allele status is not associated with A β and APOE ϵ -related cognitive decline in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019 , 76, 162-165	5.6	19
187	Comparison of F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL approaches: Validation against histopathology. <i>Alzheimer's and Dementia</i> , 2019 , 15, 807-816	1.2	26
186	val158met is not associated with A β amyloid and ϵ related cognitive decline in cognitively normal older adults. <i>IBRO Reports</i> , 2019 , 6, 147-152	2	4
185	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. <i>Science Advances</i> , 2019 , 5, eaau7220	14.3	44

184	Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid Associated Cognitive Decline in Older Adults. <i>Archives of Clinical Neuropsychology</i> , 2019 , 34, 585-598	2.7	11
183	Validation of a priori candidate Alzheimer's disease SNPs with brain amyloid-beta deposition. <i>Scientific Reports</i> , 2019 , 9, 17069	4.9	9
182	Metabolic patterns and seizure outcomes following anterior temporal lobectomy. <i>Annals of Neurology</i> , 2019 , 85, 241-250	9.4	16
181	Multisite study of the relationships between antemortem [C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. <i>Alzheimer's and Dementia</i> , 2019 , 15, 205-216	12.6	82
180	Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain Aβ amyloid burden. <i>Translational Psychiatry</i> , 2018 , 8, 47	8.6	59
179	Cognitive gene risk profile for the prediction of cognitive decline in presymptomatic Alzheimer's disease. <i>Personalized Medicine in Psychiatry</i> , 2018 , 7-8, 14-20	1.1	8
178	Reply: Cortical tau pathology: a major player in fibre-specific white matter reductions in Alzheimer's disease?. <i>Brain</i> , 2018 , 141, e45	11.2	2
177	NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018 , 14, 535-562	1.2	3155
176	Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions. <i>Nature Reviews Neurology</i> , 2018 , 14, 225-236	15	211
175	High performance plasma amyloid-β biomarkers for Alzheimer's disease. <i>Nature</i> , 2018 , 554, 249-254	50.4	733
174	KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aβ amyloid burden. <i>Scientific Reports</i> , 2018 , 8, 2034	4.9	21
173	Association of Aβ amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2018 , 75, 488-494	17.2	51
172	Amyloid burden and incident depressive symptoms in preclinical Alzheimer's disease. <i>Journal of Affective Disorders</i> , 2018 , 229, 269-274	6.6	15
171	Fibre-specific white matter reductions in Alzheimer's disease and mild cognitive impairment. <i>Brain</i> , 2018 , 141, 888-902	11.2	139
170	Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies. <i>Journal of Alzheimer's Disease</i> , 2018 , 62, 965-992	4.3	57
169	Self-reported confusion is related to global and regional Aβ amyloid: data from the Women's healthy ageing project. <i>Brain Imaging and Behavior</i> , 2018 , 12, 78-86	4.1	3
168	Presymptomatic atrophy in autosomal dominant Alzheimer's disease: Aβ serial magnetic resonance imaging study. <i>Alzheimer's and Dementia</i> , 2018 , 14, 43-53	1.2	28
167	Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1565-1571	1.2	59

166	The effect of preclinical Alzheimer's disease on age-related changes in intelligence in cognitively normal older adults. <i>Intelligence</i> , 2018 , 70, 22-29	3	8
165	Episodic Memory and Learning Dysfunction Over an 18-Month Period in Preclinical and Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018 , 65, 977-988	4.3	13
164	Implementing the centiloid transformation for C-PiB and β amyloid F-PET tracers using CapAIBL. <i>NeuroImage</i> , 2018 , 183, 387-393	7.9	47
163	Estimates of age-related memory decline are inflated by unrecognized Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018 , 70, 170-179	5.6	10
162	Trajectories of irregular word reading ability as a proxy for premorbid intelligence in Alzheimer's disease, mild cognitive impairment, and healthy aging: A longitudinal study. <i>Psychological Assessment</i> , 2018 , 30, 1308-1316	5.3	4
161	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018 , 75, 84-95	14.5	94
160	P2-364: TAU IMAGING IN ALZHEIMER'S DISEASE WITH [F-18]-MK6240, A SECOND GENERATION SELECTIVE TAU TRACER 2018 , 14, P831-P832		
159	O2-06-05: CORRELATION OF AMYLOID PET EXPRESSED IN CENTILOID UNITS WITH NEUROPATHOLOGICAL FINDINGS IN ALZHEIMER'S DISEASE 2018 , 14, P634-P634		
158	Centiloid scaling for quantification of brain amyloid with [F]flutemetamol using multiple processing methods. <i>EJNMMI Research</i> , 2018 , 8, 107	3.6	33
157	Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study. <i>Journal of Alzheimer's Disease</i> , 2018 , 66, 1193-1211	4.3	16
156	A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 423	5.3	11
155	Relationship Between Amyloid- β Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2018 , 65, 1313-1325	4.3	14
154	Sex, amyloid, and APOE ϵ 4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1193-1203	1.2	111
153	Self-Reported Physical Activity is Associated with Tau Burden Measured by Positron Emission Tomography. <i>Journal of Alzheimer's Disease</i> , 2018 , 63, 1299-1305	4.3	16
152	Amyloid burden and incident depressive symptoms in cognitively normal older adults. <i>International Journal of Geriatric Psychiatry</i> , 2017 , 32, 455-463	3.9	36
151	APOE ϵ 4 Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2017 , 57, 411-422	4.3	9
150	Optimal Reference Region to Measure Longitudinal Amyloid- β Change with F-Florbetaben PET. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 1300-1306	8.9	34
149	Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals. <i>Journal of Alzheimer's Disease</i> , 2017 , 58, 1293-1302	4.3	25

148	Biochemically-defined pools of amyloid- β in sporadic Alzheimer's disease: correlation with amyloid PET. <i>Brain</i> , 2017 , 140, 1486-1498	11.2	70
147	Increased Carbohydrate Intake is Associated with Poorer Performance in Verbal Memory and Attention in an APOE Genotype-Dependent Manner. <i>Journal of Alzheimer's Disease</i> , 2017 , 58, 193-201	4.3	9
146	A 'Disease Severity Index' to identify individuals with Subjective Memory Decline who will progress to mild cognitive impairment or dementia. <i>Scientific Reports</i> , 2017 , 7, 44368	4.9	15
145	Evaluation of Cholinergic Deficiency in Preclinical Alzheimer's Disease Using Pupillometry. <i>Journal of Ophthalmology</i> , 2017 , 2017, 7935406	2	17
144	Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults. <i>Scientific Reports</i> , 2017 , 7, 9766	4.9	38
143	Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 9, 10-20	5.2	29
142	BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF. <i>International Psychogeriatrics</i> , 2017 , 29, 1825-1834	3.4	14
141	A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017 , 3, 622-635	6	51
140	[S20102]: COMPARISON OF DIFFERENT TAU PET TRACERS AND THEIR RELATIONSHIP TO AMYLOID 2017 , 13, P541-P541		
139	F-Florbetaben PET beta-amyloid binding expressed in Centiloids. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 2053-2059	8.8	55
138	Amyloid β -associated cognitive decline in the absence of clinical disease progression and systemic illness. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 8, 156-164	5.2	15
137	Associations of neighborhood environment with brain imaging outcomes in the Australian Imaging, Biomarkers and Lifestyle cohort. <i>Alzheimer's and Dementia</i> , 2017 , 13, 388-398	1.2	15
136	A β Amyloid and Tau Imaging in Dementia. <i>Seminars in Nuclear Medicine</i> , 2017 , 47, 75-88	5.4	72
135	[P2B89]: LONGITUDINAL ASSESSMENT OF A β ACCUMULATION WITH FLUTEMETAMOL 2017 , 13, P778-P778		
134	Cerebral quantitative susceptibility mapping predicts amyloid- β -related cognitive decline. <i>Brain</i> , 2017 , 140, 2112-2119	11.2	144
133	Tau imaging with PET: an overview of challenges, current progress, and future applications. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 61, 405-413	1.4	10
132	A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease. <i>Journal of Molecular Neuroscience</i> , 2016 , 60, 354-361	3.3	33
131	Predicting Alzheimer disease from a blood-based biomarker profile: A 54-month follow-up. <i>Neurology</i> , 2016 , 87, 1093-101	6.5	23

130	Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. <i>Lancet Neurology, The</i> , 2016 , 15, 1044-53	24.1	135
129	CapAIBL: Automated Reporting of Cortical PET Quantification Without Need of MRI on Brain Surface Using a Patch-Based Method. <i>Lecture Notes in Computer Science</i> , 2016 , 109-116	0.9	5
128	The Relationship between Sleep Quality and Brain Amyloid Burden. <i>Sleep</i> , 2016 , 39, 1063-8	1.1	76
127	Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016 , 2, 19-26	5.2	54
126	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016 , 12, 292-323	1.2	832
125	Standardized Expression of 18F-NAV4694 and 11C-PiB β Amyloid PET Results with the Centiloid Scale. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1233-7	8.9	52
124	Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016 , 12, 796-804	1.2	102
123	Divergent Network Patterns of Amyloid- β Deposition in Logopenic and Amnesic Alzheimer's Disease Presentations. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2016 , 1, 24-31	3.4	3
122	Positron Emission Tomographic Imaging in Stroke: Cross-Sectional and Follow-Up Assessment of Amyloid in Ischemic Stroke. <i>Stroke</i> , 2016 , 47, 113-9	6.7	28
121	Subjective Memory Complaints in APOE ϵ 4 Carriers are Associated with High Amyloid- β Burden. <i>Journal of Alzheimer's Disease</i> , 2016 , 49, 1115-22	4.3	40
120	Concordance of Text Message Ecological Momentary Assessment and Retrospective Survey Data Among Substance-Using Men Who Have Sex With Men: A Secondary Analysis of a Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2016 , 4, e44	5.5	22
119	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. <i>Brain</i> , 2016 , 139, 2528-39	11.2	45
118	Feasibility, Acceptability, and Tolerability of Targeted Naltrexone for Nondependent Methamphetamine-Using and Binge-Drinking Men Who Have Sex with Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 72, 21-30	3.1	18
117	O2-08-02: The Tau Meter Scale for the Generation of Continuous and Categorical Measures of Tau Deposits in the Brain: Results from 18F-AV1451 and 18F-THK5351 Tau Imaging Studies 2016 , 12, P244-P244		2
116	A β -related memory decline in APOE ϵ 4 noncarriers: Implications for Alzheimer disease. <i>Neurology</i> , 2016 , 86, 1635-42	6.5	28
115	Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia. <i>Journal of Molecular Neuroscience</i> , 2016 , 60, 362-370	3.3	13
114	Untangling tau imaging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016 , 4, 39-42	5.2	1
113	Relationships between performance on the Cogstate Brief Battery, neurodegeneration, and A β accumulation in cognitively normal older adults and adults with MCI. <i>Archives of Clinical Neuropsychology</i> , 2015 , 30, 49-58	2.7	35

112	The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update. <i>Alzheimer's and Dementia</i> , 2015 , 11, 850-9	1.2	33
111	Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of ageing. <i>Neurobiology of Aging</i> , 2015 , 36, 1231-8	5.6	63
110	Beta-amyloid imaging with florbetaben. <i>Clinical and Translational Imaging</i> , 2015 , 3, 13-26	2	93
109	Amyloid- β anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study. <i>JAMA Psychiatry</i> , 2015 , 72, 284-91	14.5	114
108	Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort. <i>Alzheimer's Research and Therapy</i> , 2015 , 7, 16	9	16
107	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1924-38	27.4	842
106	¹⁸ F-FDG PET Improves Diagnosis in Patients with Focal-Onset Dementias. <i>Journal of Nuclear Medicine</i> , 2015 , 56, 1547-53	8.9	19
105	Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. <i>Alzheimer's and Dementia</i> , 2015 , 11, 964-74	1.2	288
104	Tau imaging: early progress and future directions. <i>Lancet Neurology</i> , 2015 , 14, 114-24	24.1	360
103	A β imaging with ¹⁸ F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 431-6	5.5	63
102	Amyloid- β related memory decline is not associated with subjective or informant rated cognitive impairment in healthy adults. <i>Journal of Alzheimer's Disease</i> , 2015 , 43, 677-86	4.3	54
101	P1-145: Implementation of the centiloid transformation for F-18 nav4694: Comparison with PiB 2015 , 11, P398-P398		
100	O1-01-04: A β accumulation in non-demented individuals: A longitudinal F-18-flutemetamol study 2015 , 11, P125-P125		1
99	Alzheimer's disease. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15056	51.1	755
98	Phenomenological characterization of memory complaints in preclinical and prodromal Alzheimer's disease. <i>Neuropsychology</i> , 2015 , 29, 571-81	3.8	33
97	Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid- β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. <i>Journal of Alzheimer's Disease</i> , 2015 , 48, 175-87	4.3	38
96	Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study. <i>Journal of Alzheimer's Disease</i> , 2015 , 46, 1079-89	4.3	22
95	Amyloid-Related Memory Decline in Preclinical Alzheimer's Disease Is Dependent on APOE ϵ 4 and Is Detectable over 18-Months. <i>PLoS ONE</i> , 2015 , 10, e0139082	3.7	20

94	Computer-aided detection of cerebral microbleeds in susceptibility-weighted imaging. <i>Computerized Medical Imaging and Graphics</i> , 2015 , 46 Pt 3, 269-76	7.6	24
93	APOE ϵ moderates amyloid-related memory decline in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015 , 36, 1239-44	5.6	56
92	Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2015 , 7, 105-13	5.3	63
91	Comparison of MR-less PiB SUVR quantification methods. <i>Neurobiology of Aging</i> , 2015 , 36 Suppl 1, S159-66	5.6	70
90	The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1-15.e1-4	1.2	355
89	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology, The</i> , 2014 , 13, 614-29	24.1	1985
88	Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. <i>Brain</i> , 2014 , 137, 221-31	11.2	145
87	Efficient machine learning framework for computer-aided detection of cerebral microbleeds using the Radon transform 2014 ,		10
86	Influence of BDNF Val66Met on the relationship between physical activity and brain volume. <i>Neurology</i> , 2014 , 83, 1345-52	6.5	46
85	Imago Mundi, Imago AD, Imago ADNI. <i>Alzheimer's Research and Therapy</i> , 2014 , 6, 62	9	4
84	In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 816-26	8.8	137
83	Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies. <i>Alzheimer's Research and Therapy</i> , 2014 , 6, 11	9	62
82	Among vitamin B12 deficient older people, high folate levels are associated with worse cognitive function: combined data from three cohorts. <i>Journal of Alzheimer's Disease</i> , 2014 , 39, 661-8	4.3	57
81	Al β and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 743-751.e1	1.2	62
80	Management impact of FDG-PET in dementia: results from a tertiary center memory clinic. <i>Journal of Alzheimer's Disease</i> , 2014 , 42, 885-92	4.3	12
79	Genetic algorithm with logistic regression for prediction of progression to Alzheimer's disease. <i>BMC Bioinformatics</i> , 2014 , 15 Suppl 16, S11	3.6	49
78	Personal memory function in mild cognitive impairment and subjective memory complaints: results from the Australian Imaging, Biomarkers, and Lifestyle (AIBL) Study of Ageing. <i>Journal of Alzheimer's Disease</i> , 2014 , 40, 551-61	4.3	9
77	O3-07-01: AMYLOID β RELATED COGNITIVE DECLINE IN PRECLINICAL ALZHEIMER'S DISEASE IS MODERATED BY APOE AND BDNF POLYMORPHISMS 2014 , 10, P221-P221		

76	MR-less surface-based amyloid assessment based on 11C PiB PET. <i>PLoS ONE</i> , 2014 , 9, e84777	3.7	29
75	Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer's disease: a preliminary study. <i>PLoS ONE</i> , 2014 , 9, e86498	3.7	57
74	Cerebral microbleeds: a review of clinical, genetic, and neuroimaging associations. <i>Frontiers in Neurology</i> , 2014 , 4, 205	4.1	140
73	Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year prospective cohort study. <i>British Journal of Psychiatry</i> , 2014 , 204, 400-1	5.4	22
72	Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). <i>International Psychogeriatrics</i> , 2014 , 26, 543-54	3.4	30
71	Incidence of cerebral microbleeds in preclinical Alzheimer disease. <i>Neurology</i> , 2014 , 82, 1266-73	6.5	110
70	Autobiographical narratives relate to Alzheimer's disease biomarkers in older adults. <i>International Psychogeriatrics</i> , 2014 , 26, 1737-46	3.4	4
69	Aβ imaging in Aging, Alzheimer's Disease and Other Neurodegenerative Conditions 2014 , 213-254		
68	(18)F-florbetaben Aβ imaging in mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2013 , 5, 4	9	40
67	Automatic detection of small spherical lesions using multiscale approach in 3D medical images 2013 ,		4
66	Predicting Alzheimer disease with β amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. <i>Annals of Neurology</i> , 2013 , 74, 905-13	9.4	158
65	Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. <i>Alzheimer's and Dementia</i> , 2013 , 9, e-1-16	1.2	330
64	Aβ amyloid, cognition, and APOE genotype in healthy older adults. <i>Alzheimer's and Dementia</i> , 2013 , 9, 538-45	1.2	45
63	Imaging markers for Alzheimer disease: which vs how. <i>Neurology</i> , 2013 , 81, 487-500	6.5	173
62	Research and standardization in Alzheimer's trials: reaching international consensus. <i>Alzheimer's and Dementia</i> , 2013 , 9, 160-8	1.2	16
61	O40701: Biomarker-based prediction of cognitive decline in 270 nondemented older individuals: Three-year follow-up results from the Australian Imaging Biomarkers and Lifestyle study of Aging (AIBL) 2013 , 9, P695-P695		
60	IC-O301: The Centiloid Scale: Standardization of amyloid imaging measures 2013 , 9, P8-P8		3
59	Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. <i>Lancet Neurology</i> , 2013 , 12, 357-67	24.1	1336

58	Long night's journey into the day: amyloid- β imaging in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2013 , 33 Suppl 1, S349-59	4.3	19
57	Amyloid imaging with PET in early Alzheimer disease diagnosis. <i>Medical Clinics of North America</i> , 2013 , 97, 377-98	7	45
56	BDNF Val66Met, A β amyloid, and cognitive decline in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013 , 34, 2457-64	5.6	93
55	Decline in cognitive function over 18 months in healthy older adults with high amyloid- β . <i>Journal of Alzheimer's Disease</i> , 2013 , 34, 861-71	4.3	34
54	Three-month stability of the CogState brief battery in healthy older adults, mild cognitive impairment, and Alzheimer's disease: results from the Australian Imaging, Biomarkers, and Lifestyle-rate of change substudy (AIBL-ROCS). <i>Archives of Clinical Neuropsychology</i> , 2013 , 28, 320-30	2.7	70
53	The Women's Healthy Ageing Project: fertile ground for investigation of healthy participants 'at risk' for dementia. <i>International Review of Psychiatry</i> , 2013 , 25, 726-37	3.6	14
52	Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β amyloid imaging in aging and dementia. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 880-6	8.9	121
51	Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 476-90	8.9	179
50	Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 1472-8	8.9	79
49	The association of A β amyloid and composite cognitive measures in healthy older adults and MCI. <i>International Psychogeriatrics</i> , 2013 , 25, 1667-77	3.4	21
48	Cognitive decline in adults with amnesic mild cognitive impairment and high amyloid- β prodromal Alzheimer's disease?. <i>Journal of Alzheimer's Disease</i> , 2013 , 33, 1167-76	4.3	30
47	Cognitive consequences of high A β amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease. <i>Neuropsychology</i> , 2013 , 27, 322-332	3.8	30
46	Clinical profile of PiB-positive corticobasal syndrome. <i>PLoS ONE</i> , 2013 , 8, e61025	3.7	38
45	Prediction of amyloid- β pathology in amnesic mild cognitive impairment with neuropsychological tests. <i>Journal of Alzheimer's Disease</i> , 2013 , 33, 451-62	4.3	27
44	Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials. <i>PLoS ONE</i> , 2013 , 8, e58816	3.7	33
43	Cortical surface mapping using topology correction, partial flattening and 3D shape context-based non-rigid registration for use in quantifying atrophy in Alzheimer's disease. <i>Journal of Neuroscience Methods</i> , 2012 , 205, 96-109	3	13
42	Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. <i>Neurology</i> , 2012 , 79, 1645-52	6.5	84
41	Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2012 , 34, 345-58	2.1	92

40	In vitro characterization of [18F]-florbetaben, an A β imaging radiotracer. <i>Nuclear Medicine and Biology</i> , 2012 , 39, 1042-8	2.1	45
39	Comparison of 11C-PiB and 18F-florbetaben for A β imaging in ageing and Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012 , 39, 983-9	8.8	143
38	Relationship between memory performance and β amyloid deposition at different stages of Alzheimer's disease. <i>Neurodegenerative Diseases</i> , 2012 , 10, 141-4	2.3	33
37	Differential diagnosis in Alzheimer's disease and dementia with Lewy bodies via VMAT2 and amyloid imaging. <i>Neurodegenerative Diseases</i> , 2012 , 10, 161-5	2.3	31
36	Regional dynamics of amyloid- β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. <i>Brain</i> , 2012 , 135, 2126-39	11.2	179
35	Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian imaging, biomarkers and lifestyle (AIBL) study of ageing. <i>International Psychogeriatrics</i> , 2012 , 24, 197-204	3.4	31
34	Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. <i>Brain</i> , 2011 , 134, 798-807	11.2	113
33	Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011 , 7, 280-92	1.2	4210
32	IC-03-01: Dynamic of beta-amyloid deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a PiB-PET longitudinal study 2011 , 7, S6-S6		
31	Advances in structural and molecular neuroimaging in Alzheimer's disease. <i>Medical Journal of Australia</i> , 2011 , 194, S20-3	4	3
30	Episodic memory decline predicts cortical amyloid status in community-dwelling older adults. <i>Journal of Alzheimer's Disease</i> , 2011 , 27, 627-37	4.3	31
29	Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study. <i>Neuropsychologia</i> , 2011 , 49, 2384-90	3.2	126
28	Longitudinal assessment of A β and cognition in aging and Alzheimer disease. <i>Annals of Neurology</i> , 2011 , 69, 181-92	9.4	576
27	Subtypes of progressive aphasia: application of the International Consensus Criteria and validation using β amyloid imaging. <i>Brain</i> , 2011 , 134, 3030-43	11.2	243
26	Local intensity model: An outlier detection framework with applications to white matter hyperintensity segmentation 2011 ,		4
25	Brain amyloid imaging. <i>Journal of Nuclear Medicine</i> , 2011 , 52, 1733-40	8.9	184
24	Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. <i>Journal of Nuclear Medicine</i> , 2011 , 52, 1210-7	8.9	267
23	18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. <i>Brain</i> , 2011 , 134, 1089-100	11.2	255

22	Amyloid imaging. <i>International Psychogeriatrics</i> , 2011 , 23 Suppl 2, S41-9	3.4	23
21	Quantitative approaches to amyloid imaging. <i>Methods in Molecular Biology</i> , 2011 , 680, 201-25	1.4	3
20	11C-PiB PET ABri imaging in Worster-Drought syndrome (familial British dementia): a case report. <i>Journal of Alzheimer's Disease</i> , 2010 , 19, 423-8	4.3	14
19	Larger temporal volume in elderly with high versus low beta-amyloid deposition. <i>Brain</i> , 2010 , 133, 3349-58.2	5.2	111
18	Amyloid PET Ligands for Dementia. <i>PET Clinics</i> , 2010 , 5, 33-53	2.2	20
17	Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. <i>Neurobiology of Aging</i> , 2010 , 31, 1275-83	5.6	750
16	Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. <i>Annals of Neurology</i> , 2010 , 67, 317-24	9.4	255
15	High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. <i>Archives of Neurology</i> , 2009 , 66, 1537-44		133
14	Advances in molecular imaging for the diagnosis of dementia. <i>Expert Opinion on Medical Diagnostics</i> , 2009 , 3, 705-16		11
13	Alzheimer's disease detection using 11C-PiB with improved partial volume effect correction 2009 ,		1
12	Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172. <i>Journal of Nuclear Medicine</i> , 2009 , 50, 309-15	8.9	69
11	Characterization of PiB binding to white matter in Alzheimer disease and other dementias. <i>Journal of Nuclear Medicine</i> , 2009 , 50, 198-204	8.9	76
10	Amyloid imaging in Alzheimer's disease and other dementias. <i>Brain Imaging and Behavior</i> , 2009 , 3, 246-61.1	4.1	23
9	The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. <i>International Psychogeriatrics</i> , 2009 , 21, 672-87	3.4	506
8	Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. <i>Lancet Neurology</i> , 2008 , 7, 129-35	24.1	551
7	Automated (11)C-PiB standardized uptake value ratio. <i>Academic Radiology</i> , 2008 , 15, 1376-89	4.3	17
6	The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias. <i>Molecular Neurobiology</i> , 2008 , 38, 1-15	6.2	81
5	In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. <i>Journal of Neuroscience</i> , 2007 , 27, 10365-71	6.6	130

4	Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. <i>Brain</i> , 2007 , 130, 2837-44	11.2	657
3	Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. <i>Journal of Nuclear Medicine</i> , 2007 , 48, 547-52	8.9	172
2	Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B. <i>Archives of Neurology</i> , 2007 , 64, 1140-4		64
1	In vivo microstructural heterogeneity of white matter lesions in Alzheimer's disease using tissue compositional analysis of diffusion MRI data		3